Superior Planning, LLC’s Denali Therapeutics DNLI Stock Holding History

Superior Planning, LLC’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$62	Buy	+3	New	+$70	﹤0.01%	2107

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Superior Planning, LLC's DNLI Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Denali Therapeutics (DNLI) in Q3 2026: 3 shares worth $62. The stake represents ﹤0.01% of the portfolio and ranks #2107 among its holdings.

171 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

Superior Planning, LLC held 3 shares of Denali Therapeutics worth $62 as of Q3 2026.
Denali Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Denali Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #2107 holding.
171 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.